Serum omentin, resistin and tumour necrosis factor-? levels in Behcet patients with and without ocular involvement

Basit Öğe Kaydı
dc.contributor.authorTurkcu, Fatih Mehmet
dc.contributor.authorSahin, Alparslan
dc.contributor.authorCingu, Abdullah Kursat
dc.contributor.authorKaya, Savas
dc.contributor.authorYuksel, Hatice
dc.contributor.authorCinar, Yasin
dc.contributor.authorBatmaz, Ibrahim
dc.date.accessioned2024-04-24T16:01:53Z
dc.date.available2024-04-24T16:01:53Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe objective of this study was to evaluate serum omentin, resistin and tumour necrosis factor-alpha (TNF-alpha) levels in Behcet disease (BD) patients with and without ocular involvement, as well as control subjects. Omentin, resistin and TNF-alpha levels were assessed in the plasma of 51 BD patients and compared with those of 24 control subjects. The plasma resistin and TNF-alpha levels were significantly higher in the BD patients than in the control group (p = 0.028 and p = 0.011, respectively), whereas the plasma omentin level was significantly lower in BD patients than in the control group (p = 0.035). In the ocular BD, non-ocular BD and control groups, the omentin levels were 8.9 +/- 4.65, 8.6 +/- 3.61, and 12.4 +/- 6.24 ng/mL; resistin levels were 0.29 +/- 0.21, 0.24 +/- 0.2 and 0.15 +/- 0.45 ng/mL; and TNF-alpha levels were 25.45 +/- 3.65, 24.03 +/- 2.49 and 21.93 +/- 4.86 ng/mL, respectively. Omentin/resistin and TNF-alpha/omentin ratios were more significant parameters in the demonstration of the differences in the groups; the former was lower and the latter was higher in the patient groups (p = 0.001 and p = 0.002, respectively). We demonstrated that the plasma omentin level and omentin/resistin ratio were decreased, whereas the resistin and TNF-alpha levels and TNF-alpha/omentin ratio were increased in BD patients. These ratios may be used in the presentation of deviation in the inflammatory and anti-inflammatory balance in BD.en_US
dc.description.sponsorshipDicle University DUBAPen_US
dc.description.sponsorshipWe are grateful to Dicle University DUBAP for their sponsorship of the English editing of this manuscript.en_US
dc.identifier.doi10.1007/s00417-015-3016-0
dc.identifier.endpage1568en_US
dc.identifier.issn0721-832X
dc.identifier.issn1435-702X
dc.identifier.issue9en_US
dc.identifier.pmid25904298
dc.identifier.scopus2-s2.0-84940440521
dc.identifier.scopusqualityQ1
dc.identifier.startpage1565en_US
dc.identifier.urihttps://doi.org/10.1007/s00417-015-3016-0
dc.identifier.urihttps://hdl.handle.net/11468/14461
dc.identifier.volume253en_US
dc.identifier.wosWOS:000360290700017
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofGraefes Archive For Clinical and Experimental Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBehcet Diseaseen_US
dc.subjectOmentinen_US
dc.subjectResistinen_US
dc.subjectTumour Necrosis Factor-Alphaen_US
dc.titleSerum omentin, resistin and tumour necrosis factor-? levels in Behcet patients with and without ocular involvementen_US
dc.titleSerum omentin, resistin and tumour necrosis factor-? levels in Behcet patients with and without ocular involvement
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu